Ardelyx, Inc. (ARDX) – Frank
Pitch Summary: @justfactstruth presents a detailed multi-year financial model arguing that Ardelyx is materially undervalued at current levels. The thesis centers on accelerating revenue growth driven by XPHOZAH and Ibsrela, with a transition from losses in 2025 to strong profitability by 2026 and beyond. The author projects EPS reaching $1.56 by 2027 and $2.74 by […]
